z-logo
open-access-imgOpen Access
Is the classical oral antidiabetic metformin the novel miracle drug to combat aging?
Author(s) -
Hartmut Glossmann,
O. Lutz
Publication year - 2021
Publication title -
the biochemist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.126
H-Index - 7
eISSN - 1740-1194
pISSN - 0954-982X
DOI - 10.1042/bio_2021_118
Subject(s) - metformin , medicine , diabetes mellitus , drug , type 2 diabetes , disease , pharmacology , endocrinology
Metformin is first or second choice for oral treatment of type 2 diabetes and is licensed for its prevention. Numerous articles propagate metformin as a drug that combats diseases and lowers the risks that are associated with advanced chronological age, such as cancer, diabetes, frailty, coronary heart disease and, most recently, even COVID-19. However, no clinical studies yet exist which prove that metformin delays the onset of such age-related diseases in elderly healthy individuals. Metformin – contrary to expectations – interferes with the beneficial effects of endurance or resistance training, is suspected to rapidly lead to mild anaemia and proven to cause vitamin B12 deficiency.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom